A5086680527- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular and Diving-Related Complications
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Cardiomyopathy and Myosin Studies
- Cardiovascular Effects of Exercise
- Cardiovascular Issues in Pregnancy
- Cardiac Valve Diseases and Treatments
- Mechanical Circulatory Support Devices
- Advanced MRI Techniques and Applications
- Congenital Heart Disease Studies
- Cardiovascular Syncope and Autonomic Disorders
- Viral Infections and Immunology Research
- Radiation Effects in Electronics
- Vascular anomalies and interventions
- Hemodynamic Monitoring and Therapy
- Electrostatic Discharge in Electronics
- Transplantation: Methods and Outcomes
- ECG Monitoring and Analysis
- Laser Design and Applications
Banner - University Medical Center Phoenix
2015-2025
University of Arizona
2018-2025
Banner Health
2016-2025
Banner - University Medical Center Tucson
2015-2024
University of Phoenix
2016-2024
CorVita Science Foundation
2024
Liverpool Heart and Chest Hospital
2024
Mayo Clinic in Arizona
2005-2024
St. Antonius Ziekenhuis
2024
Stanford University
2018-2021
BackgroundSince the release of second-generation cryoballoon (CB2; Arctic Front AdvanceTM, Medtronic Inc) and its design modifications with improved cooling characteristics, technique, dosing, complication profile is significantly different from that first-generation cryoballoon. A comprehensive report CB2 procedural recommendations has not been reported.ObjectiveThe purpose this study was to review current best practices a group experienced centers create user's consensus guide for...
The subcutaneous implantable cardioverter-defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the ICD cannot provide bradycardia and antitachycardia pacing. Whether modular pacing-defibrillator system comprising leadless pacemaker in wireless communication to pacing safe remains unknown.
The ADVENT randomized trial revealed no significant difference in 1-year freedom from atrial arrhythmias (AA) between thermal (radiofrequency/cryoballoon) and pulsed field ablation (PFA). However, recent studies indicate that the postablation AA burden is a better predictor of clinical outcomes than dichotomous endpoint 30-second recurrence. goal this study was to determine: 1) impact on outcomes; 2) effect modality burden. In ADVENT, symptomatic drug-refractory patients with paroxysmal...
BackgroundPulmonary vein isolation (PVI) is the cornerstone of catheter ablation to treat patients with symptomatic drug-refractory atrial fibrillation (AF).ObjectiveThe purpose this study was assess safety and efficacy PVI using cryoballoon persistent AF.MethodsSTOP Persistent AF (ClinicalTrials.gov Identifier: NCT03012841) a prospective, multicenter, single-arm, Food Drug Administration–regulated trial designed evaluate PVI-only for (continuous episodes <6 months). The primary endpoint...
A novel cryoballoon with improved refrigerant distribution promises better pulmonary vein (PV) isolation success rate without sacrificing the technology's safety profile. This study aimed to compare Arctic Front® (AF) balloon new Front Advance™ (AFA).Twenty PVs from 10 healthy dogs weighing 29.8 ± 1.1 kg were assigned ablation AF and AFA, using a 23 mm or 28 balloon. single 4-minute was performed in each vessel, no phrenic nerve monitoring. The Achieve™ mapping catheter used confirm acute...
The circuit boundaries for reentrant ventricular tachycardia (VT) have been historically conceptualized within a 2-dimensional (2D) construct, with their fixed or functional nature unresolved. This study aimed to examine the correlation between localized lines of conduction block (LOB) evident during baseline rhythm lateral isthmus that 3-dimensionally constrain VT as hyperboloid structure.A total 175 activation maps were correlated isochronal late in 106 patients who underwent catheter...
Abstract Introduction Cryoablation therapy for pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF) is well established. A novel 28 mm cryoballoon system designed operate under low pressure safely reach a lower nadir temperature and maintain constant balloon size during cooling has not been prospectively studied in large patient population safety efficacy. The FROZEN AF (NCT04133168) trial was an international multicenter, open‐label, prospective, single‐arm study on...
STOP AF PAS (Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study) is the first prospective, multicenter, 3-year study in North America to assess long-term safety and effectiveness cryoballoon for treatment patients with drug-refractory symptomatic pAF.The was required by U.S. Food Drug Administration at time approval first-generation paroxysmal atrial fibrillation (pAF). The second-generation (CB2) commercially released shortly after this trial initiated.The...